By Brittney Nichols, MPH, RN-BSN, Science and Research Specialist, GO2 for Lung Cancer New treatments, developments, and scientific breakthroughs are always one of the most exciting aspects of the annual American Society of Clinical Oncology (ASCO) conference, but this [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
Ask the Experts: When should I talk to my doctor about clinical trials? You and your doctor might want to consider joining a clinical trial any time you must decide about your treatment such as at initial diagnosis, upon [...]
Ask the Experts: "I have small cell lung cancer and my doctor mentioned the option of having prophylactic cranial irradiation (PCI) to help prevent the cancer from spreading to my brain. I know some people decide to have PCI [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung [...]
Authors: Andrew Ciupek, PhD, Associate Director of Clinical Research; Heather Law, MA, Associate Director of Lung Cancer Registry; Shanada Monestime, PharmD, BCOP, Director of Community Engaged Research; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program 2022 was an exciting [...]
Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]
Lung cancer mortality has been declining steadily in the past two decades and the good news is the pace of the improvements have picked up! Last week, the American Cancer Society released their 2022 stats and share that the [...]
On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). This approval was based on the [...]